姓  名: 呂赫喆
學  科: 生理學與病理生理學
電話/傳真: +86-10-6480 7150 / 
電子郵件: Hezhe@ioz.ac.cn
通訊地址: 北京市朝陽區大屯路甲3號院
中國科學院幹細胞與再生醫學創新研究院大樓 421房間 必威精装版app西汉姆联 器官再生與智造全國重點實驗室 100101
更多信息: 細胞異質性與命運決定研究組     

簡曆介紹:

  呂赫喆, 必威精装版app西汉姆联 膜生物學國家重點實驗室研究員。2011年於北京師範大學獲得細胞生物學博士學位,後於美國賓夕法尼亞大學、加拿大Lunenfeld-Tanenbaum研究所從事腫瘤異質性方麵的博士後研究。2020年7月加入必威精装版app西汉姆联 成立細胞異質性與命運決定研究組。研究內容圍繞膜信號在引發重大疾病的罕見細胞中的作用,利用單細胞分析技術和DNA條形碼技術研究細胞命運軌跡,並應用高通量藥物篩選技術篩選抗腫瘤先導化合物。取得了係列研究成果,分別發表於Nature、Cell Reports、Development Cell等雜誌。目前任International journal of biological sciences、Journal of Genetics and Genomics等雜誌特邀審稿人。
  現有博士研究生2名、碩士研究生2名、聯合培養研究生1名。

研究領域:

  實驗室主要聚焦細胞異質性在疾病發生、發展中的作用,結合細胞生物學和生物信息學等手段,研究(1)探尋罕見耐藥腫瘤細胞並設計靶點藥物;(2)研究細胞發生致癌基因突變後的命運軌跡;(3)研究T細胞異質性,篩選刺激T細胞向腫瘤侵襲的小分子藥物。

社會任職:

獲獎及榮譽:

承擔科研項目情況:

代表論著:

  1.  YIifang Chen, et.al. Hezhe Lu#, Yong Zhao# (2026) IL-33/TGF-β/IL-4-induced bone marrow-derived DC9 subset promotes Th9 differentiation and allergic airway inflammation. Cell Reports. 4;45(6):117519.
  2.  Yuetong Zhang, et.al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell. 12;44(1):77-93
  3.   Haifeng Lin, et.al. Hezhe Lu# (2025) CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer. Signal Transduction and Targeted Therapy. 10:335.
  4. Miao Wang, et.al. Hezhe Lu#, Xiaowei Xu#, Yusheng Cong# (2025) PTRF Confers Melanoma-Acquired Drug Resistance Through the Upregulation of EGFR. Cell Prolif. Jul 31:e70086
  5. Maoduo Zhang, et.al. Hezhe Lu# (2025) Association between treatment-related adverse events and clinical outcomes in NSCLC patients receiving neoadjuvant immunochemotherapy: a retrospective study. Curr Med Res Opin. 41(10):1933-1944
  6. Aicun Li, et.al. (2025) Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. Dev. Cell. 21;60(14):1974-1990
  7. Mingjie Ma, et.al. (2025) Symbiotic solutions for colony nutrition: Conserved nitrogen recycling within the bacterial pouch of Tetraponera ants. PNAS. 4;122(44)
  8. Hui husan Yang, et.al. Hezhe Lu# (2024) Tacrolimus Related Acute Pancreatitis: An Observational, Retrospective, Pharmacovigilance Study. Clinical Therapeutics. 46(9988)
  9. Yifang Chen, Chenxu Zhao, Han Guo, et.al., Hezhe Lu#, Lianfeng Zhang# and Yong Zhao# (2023) Wip1 inhibits neutrophil extracellular traps to promote abscess formation in mice by directly dephos. Cell Mol Immunol. 20(8):941-954
  10. Lei Guo*; Weiping Zhou*; Ziwei Xu*; Xiaoqing Cao; Shiya Wan; Ying Yi Zhang#; Jie Zhang#; Hezhe Lu#; (2023) Identification of IRAK1BP1 as a candidate prognostic factor in lung adenocarcinoma, Frontiers in Oncology, 13(1132811)
  11. Zizhu Li, Ying Yi Zhang, Haomiao Zhang, Hezhe Lu# (2022) Asymmetric Cell Division and Tumor Heterogeneity. Frontiers in Cell and Developmental Biology 10:938685
  12. Maoduo Zhang, Ying Yi Zhang, Yongze Chen, Hezhe Lu# (2021) TGF-β Signaling and Resistance to Cancer Therapy. Frontiers in Cell and Developmental Biology 9:786728.
  13. Hezhe Lu*, Shujing Liu*, Gao Zhang*, Bin Wu, et. al. (2017) PAK signalling drives   acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550:133-136. (* Equal Contribution)
  14. Hezhe Lu*, Shujing Liu*, Gao Zhang, Yi Hu, et. al. (2016) Oncogenica BRAF-induced invadopodia formation and melanoma invasion. Cell Reports. 15(9): 2012–2024. (* Equal Contribution)
  15. Hezhe Lu, Jianglan Liu, Shujing Liu, et. al. (2013) Exo70 isoform switching upon Epithelial-Mesenchymal transition mediates cancer cell invasion. Dev Cell. 27(5): 560-573
  16. Hezhe Lu, Ellen Fan, Suozhu Sun, et. al. (2009) Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem 106 (4): 738-744.

寫給考生的話:

關於我們
聯係我們
地  址:北京市朝陽區北辰西路1號院5號
郵  編:100101
電子郵件:ioz@ioz.ac.cn
電  話:+86-10-64807098
傳  真:+86-10-64807099
友情鏈接
Baidu
map